Mankind Pharma stock surges 4.5% as Q2 profit jumps 39%, revenue rises 17%

The company's market capitalisation stood at approximately Rs 95,500 crore. Mankind Pharma reported a 39.2 percent year-on-year increase in net profit to Rs 712 crore for the quarter ended September 2026, compared with Rs 511.5 crore in the corresponding quarter last year. Revenue from operations rose 17.3 percent to Rs 4,338 crore from Rs 3,697.16 crore a year earlier, reflecting double-digit growth in the company's topline.

Domestic revenue increased 14.8 percent to Rs 3,657 crore, while exports jumped 32.7 percent to Rs 681 crore. The domestic pharmaceutical business, excluding consumer healthcare, registered 15.9 percent growth, supported by strong performance in chronic and acute therapies. The company reported growth of approximately 19 percent in cardiac therapies and 16 percent in anti-diabetes products, while its international business expanded 33 percent.

Operating performance also strengthened during the quarter. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 27.1 percent year-on-year to Rs 1,171 crore, compared with Rs 921.3 crore in the year-ago period. The company's EBITDA margin expanded to 27 percent from 24.9 percent a year earlier, an improvement of 210 basis points. The results showed that operating profit grew faster than revenue, indicating improved profitability during the quarter.

Vice Chairman and Managing Director Rajeev Juneja said the company's disciplined execution and strengthening business fundamentals supported its performance. He also highlighted the recent acquisition of Armed Cell Therapeutics, marking Mankind Pharma's entry into next-generation CAR-T therapies. Mankind Pharma's rally came amid broader gains in pharmaceutical stocks, with the Nifty Pharma index advancing 1.56 percent to 25,723.85 on Monday, outperforming the benchmark indices.

Indian equity markets ended the session higher, with the Sensex gaining 372 points, or 0.5 percent, to 73,496, while the Nifty rose 117 points to 22,717, according to pre-closing auction figures. The broader markets also registered gains. The Nifty Midcap 100 index advanced 1 percent, while the Nifty Smallcap 100 climbed 1.4 percent. Market breadth remained positive, with 2,198 shares advancing against 1,888 declines, while 166 shares remained unchanged. The India VIX rose 1.54 percent to 17.12.